The said drugs are indicated for the treatment of allergic rhinitis caused by pollen and upper respiratory tract allergy for over-the-counter (OTC) use. Loratadine is an antihistamine that treats symptoms such as itching, runny nose, watery eyes, and sneezing from hay fever and other allergies. This product is generic version of Clartin tablet in the same strength of Bayer Healthcare. Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations. The company reported 15.8% increase in consolidated net profit to Rs 96.72 crore on 20.83% rise in revenue from operations to Rs 641.92 crore in Q2 FY25 over Q2 FY24.Powered by Capital Market - Live

Marksans Pharma announced the final approval of the Company's Abbreviated New Drug Application (ANDA) for Loratadine Tablets USP 10 mg from USFDA. They are indicated for the treatment of allergic rhinitis caused by pollen and upper respiratory tract allergy for over-the-counter (OTC) use. This product is generic version of Clartin tablet in the same strength of Bayer Healthcare. Loratadine is an antihistamine that treats symptoms such as itching, runny nose, watery eyes, and sneezing from hay fever and other allergies.Powered by Capital Market - Live

Net profit of Marksans Pharma rose 15.80% to Rs 96.72 crore in the quarter ended September 2024 as against Rs 83.52 crore during the previous quarter ended September 2023. Sales rose 20.83% to Rs 641.92 crore in the quarter ended September 2024 as against Rs 531.24 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales641.92531.24 21 OPM %21.1421.45 - PBDT144.11131.32 10 PBT124.60113.77 10 NP96.7283.52 16 Powered by Capital Market - Live

The firm stated that growth was witnessed across all key markets, led by US and followed by ANZ. Research & Development (R&D) spend stood at Rs 10.7 crore during the quarter, 1.7% of consolidated revenue. Profit before tax rose 9.51% to Rs 124.59 crore in September 2024 quarter as compared with Rs 113.77 crore posted in corresponding quarter previous fiscal. EBITDA climbed 19.1% to Rs 136 crore in Q2 FY25 as compared to Rs 113.9 crore in same period last year. EBITDA margin declined to 21.1% in Q2 of FY25 as compared to 21.4% in the corresponding period previous fiscal. During the quarter, revenue from US & North America stood at Rs 304.2 crore (up 37% YoY) and UK and Europe stood at Rs 246.7 crore (up 6% YoY). Revenue from Australia and New Zealand business stood at Rs 63.6 crore (up 31% YoY) in Q2 FY25. Rest of World (ROW) business grew by 1% YoY to Rs 27.5 crore during the period under review. The cash balance at the end of 30 September 2024 is at Rs 657 crore. The pharmaco received market authorization from UKMHRA for products - Levonorgestrel 1.5mg tablet, Rasagiline 1mg tablet, Olmesartan 10, 20, 40mg tablets, Fluoxetine 10, 30, 60mg tablets and Levetiracetam 100mg/ml. during the period under review. Mark Saldanha, managing director and CEO, Marksans Pharma, said, 'Q2 marks a strong performance on back of a robust Q1. Growth trajectory improved further with revenue growth of 21% YoY. We are happy to share that this growth was broad based across all our key markets, led by the US market and also driven by increased market share. We continue to witness favourable raw material prices and improved product mix, thereby leading to a gross margin expansion of 732bps YoY and an all-time high quarterly EBITDA of Rs 135.7 crore. We anticipate stronger performance in the coming quarters due to our upcoming new launches, the onset of the winter season and scaling up of the TEVA facility.' Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations. Powered by Capital Market - Live

Marksans Pharma will hold a meeting of the Board of Directors of the Company on 12 November 2024.Powered by Capital Market - Live

The inspection has been classified as voluntary action indicated (VAI) and has been closed accordingly, the firm added. Earlier, on 18 April 2024, the USFDA conducted good manufacturing practices (GMP) inspection at the company's facility located at Verna Industrial estate, Verna, Goa, India and issued five inspectional observations in Form 483. The inspection was conducted from 9 April to 17 April 2024. Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations. The pharma company reported 29.27% increase in consolidated net profit to Rs 88.75 crore in Q1 FY25 from Rs 68.66 crore in Q1 FY24. Revenue from operations jumped 18.12% YoY to Rs 590.62 crore in first quarter of FY25. The scrip rose 0.36% to Rs 221.30 on the BSE.Powered by Capital Market - Live

Marksans Pharma announced that he USFDA has issued an Establishment Inspection Report (EIR) for its manufacturing facility located at Verna, Goa and the inspection has now been successfully closed by the USFDA. USFDA has determined that the inspection classification of this facility is 'Voluntary Action Indicated' (VAI).Powered by Capital Market - Live

Marksans Pharma announced that the Annual General Meeting (AGM) of the company will be held on 24 September 2024.Powered by Capital Market - Live

Revenue from operations jumped 18.12% YoY to Rs 590.62 crore in first quarter of FY25, driven by new launches and increase in our share with existing customers in the key markets. Research & Development (R&D) spend stood at Rs 12 crore during the quarter, 2% of consolidated revenue. Profit before tax rose 23.95% to Rs 120.02 crore in June 2024 quarter as compared with Rs 96.83 crore posted in corresponding quarter previous fiscal. EBITDA climbed 26% to Rs 128.4 crore in Q1 FY25 as compared to Rs 102 crore in same period last year. EBITDA margin improved to 21.7% in Q1 of FY25 as compared to 20.4% in the corresponding period last year. During the quarter, revenue from US & North America stood at Rs 250.9 crore (up 29.8% YoY) and UK and Europe stood at Rs 251.5 crore (up 11.3% YoY). Revenue from Australia and New Zealand business stood at Rs 65.6 crore (down 12% YoY) in Q1 FY24. Rest of World (ROW) business grew by 2.1% YoY to Rs 22.7 crore during the period under review. In Q1 FY25, the capex incurred was Rs 31 crore, which is in line with the firm's plan for scaling the acquired manufacturing unit from Teva Pharma in Goa. The cash balance at the end of 30 June 2024 is at Rs 691 crore. In Q1 FY25, cash from operations was at Rs 45.3 crore and free cash flow was at 14.3 crore. The pharmaco received market authorization from UKMHRA for products Levonorgestrel 1.5mg tablets, Rasagiline 1mg tablets and Olmesartan 10, 20, 40mg tablets during the period under review. Mark Saldanha, managing director, Marksans Pharma, said, We are delighted to build on the growth momentum from the last year ' the first quarter of FY25 has shown strong start with 18% YoY increase in revenue and 26% YoY increase in EBITDA. The growth is supported by increase in share from existing customers and new launches. We experienced favorable raw material prices, however surge in freight costs continue. The shipments from the new facility have commenced to our key markets, and with that we remain optimistic for a stronger performance in the coming quarters, and our journey towards achieving the next revenue goal of Rs. 3,000 crores over the next two years.' Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations. Powered by Capital Market - Live

Net profit of Marksans Pharma rose 29.26% to Rs 88.75 crore in the quarter ended June 2024 as against Rs 68.66 crore during the previous quarter ended June 2023. Sales rose 18.12% to Rs 590.62 crore in the quarter ended June 2024 as against Rs 500.03 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales590.62500.03 18 OPM %21.7520.39 - PBDT140.46110.49 27 PBT120.0296.83 24 NP88.7568.66 29 Powered by Capital Market - Live